AMSBIO has added an important new product to its immunotherapy range - a PD-L2 / TCR activator - CHO Recombinant Cell Line.PD-L2 is one of the key players in immune checkpoint therapy, which is the focus of the 2018 Nobel Prize for Physiology & Medicine . This work pioneered by Professor James P Allison from the USA and Professor Tasuku Honjo from Japan, has led to treatments for cancers, such as melanoma, lung cancer and others based upon immune checkpoint therapy.The binding of Programmed Cell Death Protein 1 (PD-1), a receptor expressed on activated T-cells, to its…
GiroNEX Ltd – a new Cambridgeshire-based technology spin-out – has announced today first details of a novel precision powder dispensing technology that could significantly increase the pharmaceutical industry’s ability to offer patient-specific dosing for more effective treatment of specific conditions.The new GiroNEX technology can quickly dispense from 0.1 milligrams to 5 grams of pharmaceutical or other chemical powders into vials or capsules and with accuracies of 2% or better across the complete weight range. This innovative new approach has been specifically developed to target…
Genomics England names Congenica as Clinical Decision Support Service partner for the delivery of the NHS Genomic Medicine Service
17 October 2018
Cambridge Innovation Capital plc (CIC) notes that its portfolio company, Congenica, has been awarded a multi-year contract by Genomics England to be a provider of Diagnostic Decision Support Services in relation to the delivery of the UK National Health Service’s (NHS) world-leading Genomic Medicine Service.Genomics England carried out a rigorous evaluation of all the leading providers of diagnostic decision support solutions for genomics from…
Cambridge, UK, 15 October 2018 – F-star, a clinical-stage biopharmaceutical company pioneering the development of novel bispecific antibodies that target the immune system to fight cancer, today announced the appointment of Dr Eliot Forster as Chief Executive Officer. Dr Forster succeeds former CEO Dr John Haurum.
Eliot brings more than 25 years of extensive leadership experience in clinical-stage biopharmaceutical companies. Most recently, he served as CEO of Immunocore where he successfully steered the company’s strategy in immuno-oncology (IO), raising a $320M Series A and establishing…
Royalty bearing license agreement to commercialise a product incorporating the Affimer technology
Wetherby and Cambridge, UK, 10 October 2018: Avacta Group plc (AIM: AVCT), the developer of Affimer® biotherapeutics and reagents, is pleased to announce that it has agreed a commercial license with New England Biolabs® (NEB®) (Ipswich MA, USA), a global leader in the discovery and production of enzymes for molecular biology applications, to commercialise a product using the Affimer technology for use in both life science research and diagnostics assays.
Avacta and NEB have been collaborating to…
Cambridge, UK, Oct 10 2018: Owlstone Medical (or the “Company”), a global diagnostics company developing a breathalyzer for applications in early disease detection and precision medicine, today announces the appointment of Dr. Richard A Yost to its Scientific Advisory Board.
Dr. Yost, Professor and Head of Analytical Chemistry at the University of Florida, is an internationally recognized leader in the field of analytical chemistry. He has particular expertise in tandem mass spectrometry and is the co-inventor of the triple quadrupole mass spectrometer, which today represents over $1 billion…
Life science businesses can learn all about new plans to improve personalised healthcare, at an Interreg North-West Europe event, hosted by the University of Leicester and supported by Medilink Midlands.
The free CoDex4SMEs roadshow will take place on Thursday, October 11, from 09:30am until 14:30pm at Stamford Court at the University of Leicester on Manor Road (LE2 2LH). CoDex4SMEs is designed to help life-science businesses improve their use of companion diagnostics. It is a three-year programme which will run across seven countries, with nine project partners and two sub-partners.…
Acquired donor center and laboratory enables BioIVT to ship high quality blood products and blood-derived immune cells efficiently to researchers throughout Europe
Westbury, NY – Oct. 8, 2018 – BioIVT, a leading provider of research models and services for drug development, today announced that it has acquired Clinical Trials Laboratory Services (CTLS), a donor center and laboratory based in London, UK. CTLS provides dedicated high-quality serum, plasma and blood collection services. It also offers full-service cell processing capabilities on site.
“We are delighted that CTLS is now part of…
Glasgow, UK based - ScreenIn3D, a partner of AMSBIO, reports on the accolades it has received following the recent launch of its novel microfluidic cancer screening service.Combining the latest advances in microfluidics and 3D culture - the service uses an optimised screening platform targeted at improving anticancer drug treatment and accelerating development of new personalised medicine solutions.At the recent Miptec conference in Basle, Switzerland - ScreenIn3D was one of 60 global organisations invited to showcase its cutting-edge life science technologies for research, science…
Oxford, UK, 08 October 2018: Aigenpulse Ltd., (Aigenpulse), a company at the forefront of employing data technologies and advanced machine learning to accelerate drug discovery, today announced the appointment of Dr Satnam Surae as Chief Product Officer. The appointment continues the rapid expansion of the company, which has grown four-fold in the last year and is the first in a series of senior appointments.
Dr Surae was the first employee at Aigenpulse when he joined in October 2016, and most recently held the role of Lead Computational Biologist. He has extensive experience in…